EMA Rethinks HIV Trial Cohort in Light of Improved Treatments

Written on:October 8, 2013
Comments are closed

The European Medicines Agency says HIV-infected patients recruited for clinical trials should be assessed based on their documented viral resistance, rather than treatment history, as viral resistance has become rarer with the introduction of newer and better drugs in the past few years.

Source: International Pharmaceutical Regulatory Monitor


Sorry, the comment form is closed at this time.